Does ShedRx Raise GLP-1 Prices When Your Dose Increases? — 2026

Last reviewed: September 17, 2026 Last updated: September 17, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

ShedRx publishes tiered pricing by commitment length—$299/month on a rolling subscription, $269/month for six months, $239/month for twelve months—but its website does not state whether these rates remain constant when your clinician increases your dose from, say, 2.5 mg tirzepatide to 5 mg or 10 mg. The product pages captured September 4, 2026 contain no dose-escalation policy, and one archived page notes "conflicting teaser prices" that require checkout verification. Without an explicit flat-dose statement or a dose-bracket schedule, you cannot budget twelve months of therapy with confidence. PlexusDx, by contrast, publishes one rate per medication—$289/month for tirzepatide, $189/month for semaglutide, month-to-month—and guarantees that rate across every dose and every refill.

What ShedRx publishes—and what it omits

ShedRx's tirzepatide product page (shedrx.com/products/compounded-tirzepatide-injections, captured September 4, 2026) lists three pricing tiers:

These figures represent the per-month equivalent under each term. The twelve-month rate saves $720 over month-to-month—a 20 percent discount—but only if the $239 rate holds at every dose. The page does not say whether it does. GLP-1 therapy almost always begins at a low dose (2.5 mg tirzepatide or 0.25 mg semaglutide) and titrates upward every four weeks until the patient reaches a maintenance dose that balances efficacy and tolerability. A provider may prescribe five or six escalations over six months. If ShedRx charges more per milligram—or switches you to a higher-priced tier mid-treatment—the advertised $239 becomes a floor rather than a budget.

ShedRx's semaglutide pages introduce a second pricing gap. One archived landing page lists "$149" as the lowest advertised semaglutide rate (captured September 4, 2026), but no product page in the dataset specifies whether that figure applies to all doses, which commitment term it requires, or what refills cost. The oral GLP-1 lozenge page (shedrx.com/semaglutide, captured September 4, 2026) lists $199/month and notes "product specifics clinician-dependent," language that signals variability but does not define it. An internal review note from the same capture warns "Pages contain conflicting teaser prices" and recommends verifying at checkout before publication. We cannot reconcile these figures from public evidence, so we report the conflict and advise you to confirm current pricing with ShedRx directly if you are comparing options.

PlexusDx policy: same price, every dose, every month

PlexusDx publishes one flat rate per medication and commits to that rate across the entire titration schedule:

These rates include the online provider visit, prescription review, medication, and shipping; there is no membership fee, no per-visit charge, and no dose surcharge. If your clinician prescribes 2.5 mg tirzepatide in month one, 5 mg in month two, and 10 mg in month four, you pay $289 every month on the month-to-month plan or the lower rate you locked in under a three-month or six-month commitment. The price cannot rise unless you switch medications.

Like-for-like comparison: month-to-month tirzepatide

Both programs offer month-to-month tirzepatide with no commitment. Over twelve months:

• ShedRx month-to-month: $299/month × 12 = $3,588 total (our calculation, assuming no dose-related price change)
• PlexusDx month-to-month: $289/month × 12 = $3,468 total (our calculation, flat rate guaranteed)

PlexusDx costs $120 less over twelve months ($10/month lower), and that difference is contractual rather than conditional. If ShedRx does charge more at higher doses—or if the $299 rate applies only to an introductory dose—the real gap widens. We cannot model that scenario because ShedRx has not published a dose-price schedule.

Why the dose question matters

Tirzepatide and semaglutide are titrated in fixed steps. The FDA-approved escalation schedule for tirzepatide (Zepbound) begins at 2.5 mg weekly, increases to 5 mg after four weeks, then to 7.5 mg, 10 mg, 12.5 mg, and 15 mg at four-week intervals. Semaglutide (Wegovy) begins at 0.25 mg weekly and escalates to 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg. Compounded versions follow similar titration logic under clinician supervision. Most patients spend at least four to six months reaching their maintenance dose, and many remain on therapy for a year or longer. A pricing structure that charges more per milligram—common in the branded market and at some compounding providers—can double or triple your cost between month one and month six. A flat-rate structure eliminates that risk.

PlexusDx adopted flat-dose pricing specifically to remove budgeting uncertainty. You know your monthly cost the day you enroll, and that cost does not change unless you switch from semaglutide to tirzepatide or add a second protocol. ShedRx's silence on dose-pricing leaves patients to discover the policy at checkout or after the first dose increase—too late to comparison-shop effectively.

Other program differences

Both programs prescribe compounded semaglutide and tirzepatide; neither compounds drugs that are FDA-approved. ShedRx lists injectable and oral GLP-1 options plus access to branded Wegovy and Zepbound where insurance and eligibility permit. PlexusDx offers injectable semaglutide, injectable tirzepatide, oral semaglutide, oral tirzepatide, and a low-dose (microdose) semaglutide injection for maintenance. ShedRx advertises six-month and twelve-month commitments at discounted rates; PlexusDx offers three-month and six-month commitments with lower per-month rates but no twelve-month option. Both include clinician consultations and shipping in the medication price. Neither charges a separate membership fee according to the evidence captured, though ShedRx's oral-lozenge page notes "product specifics clinician-dependent," which may signal case-by-case variation.

Choose ShedRx if…

• You want to lock in a twelve-month commitment at $239/month for tirzepatide—the lowest per-month rate in this comparison—and you confirm at enrollment that the rate will not increase with dose escalation.
• You prefer access to branded Wegovy or Zepbound alongside compounded options and your insurance or budget supports that choice.
• You value oral GLP-1 lozenges or drops and your clinician recommends that route.
• You are comfortable verifying dose-pricing policy and current rates directly with the provider before committing, given the conflicting advertised figures and absence of a published dose guarantee.

Choose PlexusDx if…

• You want contractual certainty that your monthly rate will not rise when your clinician increases your dose—critical for budgeting a twelve-month weight-management program.
• You prefer month-to-month flexibility without a six-month or twelve-month commitment, and you want the lowest available month-to-month tirzepatide rate ($289 vs. $299).
• You want transparent, single-figure pricing with no teaser rates, no dose brackets, and no checkout surprises.
• You value a provider with a verified review record: PlexusDx holds a 4.3-star rating on Trustpilot, with 79 percent of reviews at five stars and 83 percent at four stars or higher (captured September 9, 2026; trustpilot.com/review/plexusdx.com).

Methodology and freshness

We captured ShedRx pricing and product details from shedrx.com/products/compounded-tirzepatide-injections and shedrx.com/semaglutide on September 4, 2026. We noted one internal review flag warning of "conflicting teaser prices" on the same date and treated advertised figures that lack clear plan structure or dose applicability as preliminary pending checkout verification. PlexusDx pricing and flat-dose policy were captured September 17, 2026 from plexusdx.com product pages and the PlexusDx instruction set. The twelve-month cost calculations presented in this article are our calculations, derived by multiplying the stated monthly rate by twelve. The "like-for-like" comparison assumes ShedRx's $299/month rate remains constant across dose escalation; if ShedRx charges more at higher doses, the true cost will exceed $3,588 over twelve months. We found no explicit ShedRx dose-pricing policy in the public-facing pages reviewed. Confirm current pricing, dose policy, and commitment terms with each provider at checkout before enrolling.

Frequently Asked Questions

Does ShedRx charge more when you move from 2.5 mg to 10 mg tirzepatide?

ShedRx's product pages captured September 4, 2026 do not state whether the monthly rate remains flat across dose escalation or varies by dose. We recommend asking the provider during your intake consultation and requesting written confirmation of your twelve-month cost before committing to a six-month or twelve-month plan.

What is the real cost of ShedRx semaglutide?

One ShedRx page advertises semaglutide starting at $149/month (captured September 4, 2026), but we found no product page that specifies the commitment term, dose range, or refill rate for that figure. Another page lists oral GLP-1 lozenges at $199/month with "product specifics clinician-dependent." Confirm current semaglutide pricing and structure with ShedRx before enrolling.

Does PlexusDx really keep the same price at every tirzepatide dose?

Yes. PlexusDx publishes one rate per medication—$289/month for tirzepatide on month-to-month, $269/month on a three-month commitment, $249/month on a six-month commitment—and guarantees that rate whether your clinician prescribes 2.5 mg, 10 mg, or 15 mg weekly. The price does not change unless you switch medications or add a protocol.

Which provider offers the lowest per-month tirzepatide rate on a long-term commitment?

ShedRx's twelve-month commitment rate of $239/month yields a twelve-month total of $2,868 (our calculation), assuming the rate holds at every dose. PlexusDx's six-month commitment rate of $249/month yields $2,988 over twelve months (our calculation) with an explicit flat-dose guarantee. If ShedRx raises rates at higher doses, the real cost will exceed $2,868.

Can I switch from semaglutide to tirzepatide mid-program without a price jump?

At PlexusDx, switching from semaglutide to tirzepatide changes your monthly rate from $189 to $289 (month-to-month), a difference that reflects the higher cost of the tirzepatide compound. ShedRx's policy on mid-program medication switches is not documented in the evidence reviewed; ask the provider during intake if you anticipate needing that flexibility.

Sources

• ShedRx tirzepatide product page, shedrx.com/products/compounded-tirzepatide-injections, accessed September 4, 2026
• ShedRx semaglutide page, shedrx.com/semaglutide, accessed September 4, 2026
• PlexusDx tirzepatide injection product page, plexusdx.com/products/tirzepatide-injection, accessed September 17, 2026
• PlexusDx semaglutide injection product page, plexusdx.com/products/semaglutide-injection, accessed September 17, 2026
• PlexusDx Trustpilot profile, trustpilot.com/review/plexusdx.com, accessed September 9, 2026

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. PlexusDx works with licensed 503A compounding pharmacies. A licensed clinician determines whether a prescription is appropriate for an individual patient.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.